About The Study: In two pivotal phase 3 clinical trials, elinzanetant, a selective neurokinin-1,3 receptor antagonist, demonstrated statistically significant reductions in vasomotor symptoms (VMS) frequency and severity vs placebo in postmenopausal individuals with moderate to severe VMS. Elinzanetant also significantly improved sleep disturbances and menopause-related quality of life vs placebo; the safety profile was favorable.
About The Study: In two pivotal phase 3 clinical trials, elinzanetant, a selective neurokinin-1,3 receptor antagonist, demonstrated statistically significant reductions in vasomotor symptoms (VMS) frequency and severity vs placebo in postmenopausal individuals with moderate to severe VMS. Elinzanetant also significantly improved sleep disturbances and menopause-related quality of life vs placebo; the safety profile was favorable.
Corresponding Author: To contact the corresponding author, JoAnn V. Pinkerton, MD, MSCP, email JVP9U@uvahealth.org.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jama.2024.14618)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA
